Johnson & Johnson Sells Off After Earnings

Johnson & Johnson (JNJ) reported revenue of $20.01 billion and eps of $2.06. The company delivered a revenue and earnings beat, but the stock is off about 3.5% post-earnings. Below is my takeaway on the quarter.

Single Digit Organic Revenue Growth

All three of Johnson & Johnson's (JNJ) key product segments experienced revenue growth last quarter. Consumer was up 5%, Pharmaceutical (49% of total revenue) was up 19% and Medical Devices (34% of total revenue) grew 13%. I expect revenue growth from Consumer and Medical Devices to be steady going forward, but Pharmaceutical could the wild card. It could determine if the company's stated revenue growth remains in the double-digit range or not.

READ FULL ARTICLE HERE